Drug
In10018 IN Combination With Rnk08954
In10018 IN Combination With Rnk08954: highest development phase Phase 1/2, developed by InxMed (Shanghai) Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- InxMed (Shanghai) Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| IN10018 in combination with RNK08954 NCT07441174 | Phase 1/2 | Solid Tumor Cancer |
Latest
No recent events.
Follow In10018 IN Combination With Rnk08954 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.